Background: Sarcopenia (muscle weakness) characterized by a decrease in muscle mass, strength and performance is a condition that increases with old age. Sarcopenia can be seen in 5-13% of patients hospitalized in ICU where various treatment methods are used to prevent this weakness, the rate increases in patients with sepsis/ septic shock. Muscle treatment methods are used to prevent sarcopenia in similar patients hospitalized in ICU. It is predicted that "neuromuscular electrical stimulator-NMES" treatment may increase muscle mass and strength in patients who's can not be exercised actively. In this study, the contribution of NMES treatment to prevent the development of muscle weakness in patients with a diagnosis of sepsis/ septic shock followed in intensive care units (ICU) was evaluated.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Effects of NMES treatment on ICU-AW development, anthropometric measurement,
Timeframe: 28 DAYS
Effects of NMES treatment on ICU-AW development, ultrasonographic measurement
Timeframe: on the 1st, 3rd, 7th, 14th, 21st and 28th days
Effects of NMES treatment on ICU-AW development, scoring systems.
Timeframe: on the 1st, 3rd, 7th, 14th, 21st and 28th days
Effects of NMES treatment on ICU-AW development, scoring systems.
Timeframe: on the 1st, 3rd, 7th, 14th, 21st and 28th days
Effects of NMES treatment on ICU-AW development, scoring systems.
Timeframe: first day
Effects of NMES treatment on ICU-AW development, scoring systems.
Timeframe: first day
Effects of NMES treatment on ICU-AW development, scoring systems.
Timeframe: 28 days
Effects of NMES treatment on ICU-AW development, scoring systems.
Timeframe: 28 days
Effects of NMES treatment on ICU-AW development, nutrition.
Timeframe: 28 days
height
Timeframe: first day and last day ( end of the 28th day)
weight
Timeframe: first day and last day (end of the 28th day)